Dr. Nathan J. Robison, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
4650 W Sunset Blvd
Los Angeles, CA 90027
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- University of Southern California Keck School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2008
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Southern California Keck School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MA license 238951 · CA license A86955 (first issued 2004; current) -
Emergency Medicine Physician
CA license A86955 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Childrens Hospital Los Angeles Medical Group Inc (295 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $3,263 in total to this clinician.
| Day One Biopharmaceuticals | $3,155 |
|---|---|
| Springworks Therapeutics, Inc. | $108 |
| Honoraria | $3,150 |
|---|---|
| Food and Beverage | $113 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Day One Biopharmaceuticals Dec 17, 2025 | Honoraria OJEMDA · ONCOLOGY | $3,150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $158,135 in research payments for these studies, mostly to the institutions running them.
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals · Active, not recruiting · NCT05566795 - Phase i study of MEK162 for children with low grade gliomas and other rasraferk pathway activated tumors
Array Biopharma Inc - MEK-NF-201
Springworks Therapeutics, Inc. - This is a US observational registry of pediatric NF1 PN participants treated with selumetinib.
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.